Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick

13d ago, source: Zacks.com on MSN

One stock that might be an intriguing choice for investors right now is Trevi Therapeutics, Inc TRVI. This is because this ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript

27d ago, source: InvestingChannel on MSN

Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. TRVI isn't one of the ...

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

28d ago, source: WCBD

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic ...

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

8d ago, source:

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics Inc TRVI

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials

29d ago, source: Yahoo Finance

Warning! GuruFocus has detected 3 Warning Signs with TRVI. On March 20, 2024, Trevi Therapeutics Inc (NASDAQ:TRVI) released its 8-K filing, disclosing its fourth quarter and full-year financial ...

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

15d ago, source: WOOD-TV

About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of ...

Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript

28d ago, source: Seeking Alpha

Good afternoon, and welcome to the Trevi Therapeutics Fourth Quarter and Year-End 2023 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions ...

Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

28d ago, source: Finanznachrichten

March 20, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the ...